Anti-Diabetes Drugs - Mauritius

Mauritius

The Anti-Diabetes Drugs market in Mauritius is expected to achieve a projected revenue of US$9.11m in 2024.
Furthermore, it is anticipated that the revenue will demonstrate an annual growth rate (CAGR 2024-2029) of 8.23%, resulting in a market volume of US$13.53m by 2029.
In a global context, United States is projected to generate the highest revenue, amounting to US$37,840.00m in 2024.
Mauritius is witnessing a growing demand for innovative and affordable anti-diabetes drugs, as the prevalence of diabetes in the country continues to rise.

Key regions: India, Australia, Italy, Europe, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The prevalence of diabetes in Mauritius is one of the highest in the world, with more than 20% of the population being affected by the disease. As a result, the demand for anti-diabetes drugs in the country has been on the rise in recent years.

Customer preferences: The majority of the anti-diabetes drugs in Mauritius are prescribed by doctors and are only available with a prescription. However, there is a growing trend towards the use of alternative therapies such as herbal remedies and traditional medicines.

Trends in the market: The market for anti-diabetes drugs in Mauritius has been growing steadily in recent years, driven by the high prevalence of diabetes in the country. In addition, the government has taken several measures to improve access to healthcare and to promote the use of generic drugs, which has helped to increase the availability of anti-diabetes drugs in the country.

Local special circumstances: One of the unique challenges facing the anti-diabetes drugs market in Mauritius is the high prevalence of obesity in the country. Obesity is a major risk factor for diabetes, and as such, there is a growing need for drugs that can help to manage both conditions.

Underlying macroeconomic factors: The Mauritian economy has been growing steadily in recent years, driven by the country's strong tourism industry and its growing reputation as a hub for financial services. This has helped to increase the purchasing power of consumers in the country, which has in turn led to an increase in demand for healthcare services and products, including anti-diabetes drugs. Additionally, the government has been investing heavily in healthcare infrastructure and services, which has helped to improve access to healthcare and to increase the availability of anti-diabetes drugs in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.